



BCAC Submission to the Health Select Committee re: Terre Maize petition for funding of Ibrance and Kadcylla:

KEY MESSAGES:

- ✘ NZ has an appalling record in the treatment of those with advanced breast cancer:**
 - **16 months** is the median survival time from diagnosis for **NZ women** with this disease, compared to **2-3 years or longer in other Western countries**
 - Only **5% of Maori** with advanced breast cancer will be alive after 5 years; **15% of non-Maori** will survive this long.

- ✘ NZ has a two-tier system when it comes to cancer care and outcomes:**
 - Those who can afford to pay live longer than those who cannot
 - Recent NZ research shows that advanced breast cancer patients receiving public care have a **95% higher chance of dying** than those receiving private care.

- ✘ Even with the best screening and prevention programmes in place, significant numbers of NZers will still get advanced cancer and they deserve good quality care.**

- ✘ The medicines budget must be increased substantially to bring it into line with other OECD countries:**
 - NZ spends **\$199 per person per year** on medicines, compared to the 2016 **OECD average of \$951**
 - NZ spends **only 5%** of its health budget on medicines; the **OECD average is 14%**
 - NZ spends **0.34% of its GDP** on medicines; the **OECD average is 1.4% of GDP**
 - NZ consistently ranks **19th or last out of 20 OECD** countries in access to new medicines.

- ✘ Ibrance and Kadcylla are proven medicines that can improve and extend lives of NZers with BC; they actually do 'what it says on the tin'.**

- ✘ Delay in funding these medicines is killing women, and causing personal and financial stress and lasting harm to their families and communities.**

- ✘ Low and slow access to cancer medicines is not cost-effective** – it results in significant costs to the health system, the economy, and our society.

- ✘ We cannot wait until medicines are off-patent (10 years), before providing them to NZers.**

- ✘ PHARMAC's funding and operations need external independent review** – especially timeliness, transparency and impacts on people and their length and quality of life.

- ✘ PHARMAC's KPIs need to reflect the critical role that it plays in determining the health and wellbeing of NZers.**

- ✘ We need to double the medicines budget** if NZ is to deliver the quality of care to cancer and other patients that would be expected in a developed country.